Solving the mystery of the FMC63-CD19 affinity
Abstract The majority of approved CAR T cell products are based on the FMC63-scFv directed against CD19. Surprisingly, although antigen binding affinity is a major determinant for CAR function, the affinity of the benchmark FMC63-scFv has not been unambiguously determined. That is, a wide range of a...
Main Authors: | Jacqueline Seigner, Charlotte U. Zajc, Sarah Dötsch, Caroline Eigner, Elisabeth Laurent, Dirk H. Busch, Manfred Lehner, Michael W. Traxlmayr |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2023-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-023-48528-0 |
Similar Items
-
Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy
by: Katja Seipel, et al.
Published: (2023-06-01) -
T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts
by: Fatemeh Nasiri, et al.
Published: (2023-02-01) -
Soil–water characterictic curve (SWCC) for FMC Kaolin
by: Anis Amira, Abdul Karim
Published: (2015) -
Acceptance of SAP systems : a study at FMC technologies /
by: 459056 Loganathan Rajakili, et al.
Published: (2008) -
Solving the mystery of myelodysplasia.
by: Jerald Radich
Published: (2008-02-01)